Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
Date:12/16/2008

EMERYVILLE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. (Celtic) has provided an update on XERECEPT(R).

NTI sold the worldwide rights and assets related to XERECEPT to Celtic in November 2005. NTI is entitled to receive milestone payments upon the achievement of certain regulatory approvals, and if XERECEPT is approved for commercial sale, NTI is also entitled to receive profit-sharing payments on sales in the United States and royalties on sales elsewhere in the world.

"We are very pleased at the effort Celtic has applied to this project, bringing it to the point of producing, understanding and presenting solid clinical data to the medical community while simultaneously undertaking a preclinical program to expand the future potential applications of XERECEPT," said Paul E. Freiman, president and chief executive officer. "Further, our partnership has flourished on a personal basis and we both feel each party has added value to the collaboration."

    The text of the press release from Celtic is as follows:

       "Celtic Pharma Announces Update on Status of XERECEPT(R) Program
                            Sale Planned in 2009"

     "New York, London and Bermuda, December 16, 2008 - Celtic Pharmaceutical
     Holdings L.P. ("Celtic Pharma")announced today that the databases have
     been locked and preliminary analyses completed on the two double-blinded
     studies of XERECEPT(R) (corticorelin acetate), as a treatment for
     peritumoral brain edema, as well as an initial database lock on the
     open-label study of XERECEPT's long-term safety and efficacy.

     "The results of these studies are the subject of several abstract
     submissions for the American Society of Clinical Oncolo
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
2. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
3. Neurobiological Technologies Sets Date for First Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
6. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
8. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
9. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
10. Neurobiological Technologies CEO to Retire on December 31, 2008
11. Neurobiological Technologies Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... are efficient but involve a range of resource ... seed) and pine resin and a clever recycling ... a highly interesting alternative. Their study will be ... . , ,We think our discovery can open ... the batteries of the future, says Daniel Brandell, ...
(Date:9/29/2014)... September 29, 2014 ... "Epigenetics Market by Product (Modifying Enzymes, DNA Polymerase, ... Conversion Kit, Reagents), by Research Area (Developmental ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, opportunities, current market trends, and strategies ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 ACEA ... Yale University the 2014 iCELLigence Research Grant for ... ACEA’s iCELLigence instrument is an impedance based real-time ... candidate in Department of Biomedical Engineering at Yale ... Chen’s research projects in Professor Rong Fan's ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... NORTH VANCOUVER, BC, July 23 /PRNewswire-FirstCall/ - Chromos ... that the,securities commissions or similar regulatory authorities in ... Quebec have revoked the,cease trade orders against the ... are currently no cease trade orders outstanding against ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") announced ... of a proposed Phase 3 clinical study for,its ... Drug Administration,s (the,"FDA") Division of Cardiovascular and Renal ... FDA, including a face-to-face,meeting held on April 16, ...
... 23 Tengion Inc., a clinical,stage biotechnology company focused ... it has appointed Mark Stejbach as Vice,President, Marketing and ... marketing, sales, finance, and managed care experience from,both Merck ... very pleased to welcome Mark to the Tengion executive ...
Cached Biology Technology:Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning 2
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Thanks to laws of elementary electrostatics, we can easily ... and therefore predict their movements. Submerge those particles ... the calculation grows more complex. The charged particles, movements ... or otherwise alter the particles, paths. In this environment ...
... Kevlar and other synthetic fabrics: Step aside. If new ... blouses and other garments made from fibers modeled after ... called the hagfish. The study appears in ACS, journal ... supervisor Douglas S. Fudge and colleagues explain that petroleum ...
... Mainz, Germany and the renowned School of Medicine at ... This strategic partnership promises to provide an innovative stimulus ... University Medical Center. The resulting regular exchange will benefit ... "Our aim is to arrive at a better ...
Cached Biology News:Outside a vacuum: Model predicts movement of charged particles in complex media 2Mainz University Medical Center agrees partnership with Yale University 2
... designed to stabilize the biomolecules during ... There are neither animal proteins ... a convenient 10 times solution in ... to other traditional lyophilizing additives such ...
... benchtop incubator-shaker, has the smallest footprint of all ... 540 x 680 mm (W x D) does ... 505 x 510mm). Available in 25 mm or ... for shaking applications requiring controlled speed and temperature ...
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Biology Products: